Literature DB >> 30914429

Cross-Talk between Receptor Tyrosine Kinases AXL and ERBB3 Regulates Invadopodia Formation in Melanoma Cells.

Or-Yam Revach1, Oded Sandler1, Yardena Samuels1, Benjamin Geiger2.   

Abstract

The invasive phenotype of metastatic cancer cells is accompanied by the formation of actin-rich invadopodia, which adhere to the extracellular matrix and degrade it. In this study, we explored the role of the tyrosine kinome in the formation of invadopodia in metastatic melanoma cells. Using a microscopy-based siRNA screen, we identified a series of regulators, the knockdown of which either suppresses (e.g., TYK2, IGFR1, ERBB3, TYRO3, FES, ALK, PTK7) or enhances (e.g., ABL2, AXL, CSK) invadopodia formation and function. Notably, the receptor tyrosine kinase AXL displayed a dual regulatory function, where both depletion or overexpression enhanced invadopodia formation and activity. This apparent contradiction was attributed to the capacity of AXL to directly stimulate invadopodia, yet its suppression upregulates the ERBB3 signaling pathway, which can also activate core invadopodia regulators and enhance invadopodia function. Bioinformatic analysis of multiple melanoma cell lines points to an inverse expression pattern of AXL and ERBB3. High expression of AXL in melanoma cells is associated with high expression of invadopodia components and an invasive phenotype. These results provide new insights into the complexity of metastasis-promoting mechanisms and suggest that targeting of multiple invadopodia signaling networks may serve as a potential anti-invasion therapy in melanoma. SIGNIFICANCE: These findings uncover a unique interplay between AXL and ERBB3 in invadopodia regulation that points to the need for combined therapy in order to prevent invadopodia-mediated metastasis in melanoma. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 30914429     DOI: 10.1158/0008-5472.CAN-18-2316

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  Mechanisms and roles of podosomes and invadopodia.

Authors:  Stefan Linder; Pasquale Cervero; Robert Eddy; John Condeelis
Journal:  Nat Rev Mol Cell Biol       Date:  2022-09-14       Impact factor: 113.915

2.  The GAS6-AXL signaling pathway triggers actin remodeling that drives membrane ruffling, macropinocytosis, and cancer-cell invasion.

Authors:  Daria Zdżalik-Bielecka; Agata Poświata; Kamila Kozik; Kamil Jastrzębski; Kay Oliver Schink; Marta Brewińska-Olchowik; Katarzyna Piwocka; Harald Stenmark; Marta Miączyńska
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-13       Impact factor: 11.205

3.  HER3 expression and MEK activation in non-small-cell lung carcinoma.

Authors:  Thubeena Manickavasagar; Wei Yuan; Suzanne Carreira; Bora Gurel; Susana Miranda; Ana Ferreira; Mateus Crespo; Ruth Riisnaes; Chloe Baker; Mary O'Brien; Jaishree Bhosle; Sanjay Popat; Udai Banerji; Juanita Lopez; Johann de Bono; Anna Minchom
Journal:  Lung Cancer Manag       Date:  2021-04-09

4.  PLK1 and NOTCH Positively Correlate in Melanoma and Their Combined Inhibition Results in Synergistic Modulations of Key Melanoma Pathways.

Authors:  Shengqin Su; Gagan Chhabra; Mary A Ndiaye; Chandra K Singh; Ting Ye; Wei Huang; Colin N Dewey; Vijayasaradhi Setaluri; Nihal Ahmad
Journal:  Mol Cancer Ther       Date:  2020-11-11       Impact factor: 6.009

Review 5.  TYK2: An Upstream Kinase of STATs in Cancer.

Authors:  Katharina Wöss; Natalija Simonović; Birgit Strobl; Sabine Macho-Maschler; Mathias Müller
Journal:  Cancers (Basel)       Date:  2019-11-05       Impact factor: 6.639

6.  p85β regulates autophagic degradation of AXL to activate oncogenic signaling.

Authors:  Ling Rao; Victor C Y Mak; Yuan Zhou; Dong Zhang; Xinran Li; Chloe C Y Fung; Rakesh Sharma; Chao Gu; Yiling Lu; George L Tipoe; Annie N Y Cheung; Gordon B Mills; Lydia W T Cheung
Journal:  Nat Commun       Date:  2020-05-08       Impact factor: 14.919

Review 7.  AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma.

Authors:  Siyang Yan; Niels Vandewalle; Nathan De Beule; Sylvia Faict; Ken Maes; Elke De Bruyne; Eline Menu; Karin Vanderkerken; Kim De Veirman
Journal:  Cancers (Basel)       Date:  2019-11-05       Impact factor: 6.639

8.  Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report.

Authors:  Peiwei Chai; Chuandi Zhou; Renbing Jia; Yefei Wang
Journal:  Diagn Pathol       Date:  2020-01-04       Impact factor: 2.644

Review 9.  Inhibitors of HSP90 in melanoma.

Authors:  Aleksandra Mielczarek-Lewandowska; Mariusz L Hartman; Malgorzata Czyz
Journal:  Apoptosis       Date:  2020-02       Impact factor: 4.677

10.  AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells.

Authors:  Olivier Zajac; Renaud Leclere; André Nicolas; Didier Meseure; Caterina Marchiò; Anne Vincent-Salomon; Sergio Roman-Roman; Marie Schoumacher; Thierry Dubois
Journal:  Cells       Date:  2020-01-19       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.